Shigella flexneri 2a Strain CVD 1207, with Specific Deletions in virG, sen, set, and guaBA, Is Highly Attenuated in Humans
A phase 1 clinical trial was conducted among 35 healthy adult volunteers to evaluate the safety, immunogenicity, and shedding of different doses of CVD 1207, a live attenuated Shigella flexneri 2a vaccine candidate with specific deletion mutations in virG, sen, set, and guaBA. CVD 1207 retains the a...
שמור ב:
| הוצא לאור ב: | Infect Immun |
|---|---|
| Principais autores: | , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
American Society for Microbiology (ASM)
2000
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC97245/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/10678904/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/iai.68.3.1034-1039.2000 |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|
